Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C12H14O35S8.8K.7H2O |
Molecular Weight | 1413.632 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O.O.O.O.O.[K+].[K+].[K+].[K+].[K+].[K+].[K+].[K+].[O-]S(=O)(=O)OC[C@H]1O[C@@](COS([O-])(=O)=O)(O[C@H]2O[C@H](COS([O-])(=O)=O)[C@@H](OS([O-])(=O)=O)[C@H](OS([O-])(=O)=O)[C@H]2OS([O-])(=O)=O)[C@@H](OS([O-])(=O)=O)[C@@H]1OS([O-])(=O)=O
InChI
InChIKey=ZLYYTLMQNBUBHA-NGOJJLSFSA-F
InChI=1S/C12H22O35S8.8K.7H2O/c13-48(14,15)37-1-4-6(43-51(22,23)24)8(45-53(28,29)30)9(46-54(31,32)33)11(40-4)42-12(3-39-50(19,20)21)10(47-55(34,35)36)7(44-52(25,26)27)5(41-12)2-38-49(16,17)18;;;;;;;;;;;;;;;/h4-11H,1-3H2,(H,13,14,15)(H,16,17,18)(H,19,20,21)(H,22,23,24)(H,25,26,27)(H,28,29,30)(H,31,32,33)(H,34,35,36);;;;;;;;;7*1H2/q;8*+1;;;;;;;/p-8/t4-,5-,6-,7-,8+,9-,10+,11-,12+;;;;;;;;;;;;;;;/m1.............../s1
DescriptionCurator's Comment: Description was created using several sources including
http://www.drugbank.ca/drugs/DB01901; https://www.ncbi.nlm.nih.gov/pubmed/18540049; https://www.ncbi.nlm.nih.gov/pubmed/19686789; https://www.ncbi.nlm.nih.gov/pubmed/20053992
Curator's Comment: Description was created using several sources including
http://www.drugbank.ca/drugs/DB01901; https://www.ncbi.nlm.nih.gov/pubmed/18540049; https://www.ncbi.nlm.nih.gov/pubmed/19686789; https://www.ncbi.nlm.nih.gov/pubmed/20053992
Sucrosofate (sucrose octasulfate) is a class of organic compounds known as disaccharide sulfates carrying one or more sulfate group on a sugar unit. It is used to encapsulate some anticancer drugs in liposomes allowing for highly active formulations against solid tumors and immunotargeting to cancer-overexpressing cell surface receptors. ONIVYDE (liposomal irinotecan) for intravenous use encapsulates an aqueous space containing irinotecan in a gelated or precipitated state as the sucrose octasulfate salt was initially approved by FDA in 1996 for treatment of pancreatic cancer. Sucrose octasulfate (SOS), a chemical analogue of heparin, has been demonstrated to activate fibroblast growth factors signalling pathways and SOS-mediated dimerization of FGF1 was observed. SOS can suppress thrombin generation in plasma that suggests a potential for oversulfated disaccharides in controlling heparin cofactor II -regulated thrombin generation.
Originator
Sources: https://www.google.com/patents/US9364473
Curator's Comment: Liposomal irinotecan - irinotecan sucrose octasulfate salt liposome injection
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ONIVYDE Approved UseONIVYDE is a topoisomerase inhibitor indicated, in combination with fluorouracil and leucovorin, for the treatment of patients with metastatict adenocarcinoma of pancreas after disease progression following gemcitabine-based therapy. Launch Date1996 |
PubMed
Title | Date | PubMed |
---|---|---|
Science review: The use of proton pump inhibitors for gastric acid suppression in critical illness. | 2005 Feb |
|
Therapeutic paint of cidofovir/sucralfate gel combination topically administered by spraying for treatment of orf virus infections. | 2009 Jun |
|
Topical use of sucralfate in epithelial wound healing: clinical evidences and molecular mechanisms of action. | 2010 Jan |
|
Development of a highly stable and targetable nanoliposomal formulation of topotecan. | 2010 Jan 4 |
Sample Use Guides
In Vivo Use Guide
Curator's Comment: ONIVYDE is a sterile, white to slightly yellow opaque isotonic liposomal dispersion. Each 10 mL single-dose vial contains 43 mg irinotecan free base at a concentration of 4.3 mg/mL. The liposome is a unilamellar lipid bilayer vesicle, approximately 110 nm in diameter, which encapsulates an aqueous space containing irinotecan in a gelated or precipitated state as the sucrose octasulfate salt
Recommended dose of ONIVYDE is 70 mg/m^2 intravenous infusion over 90 minutes every two weeks. Recommended starting dose of ONIVYDE in patients homozygous for
UGT1A1*28 is 50 mg/m^2 every two weeks.There is no recommended dose of ONIVYDE for patients with serum
bilirubin above the upper limit of normal.
Route of Administration:
Intravenous
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C802
Created by
admin on Sat Dec 16 05:50:33 GMT 2023 , Edited by admin on Sat Dec 16 05:50:33 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C152445
Created by
admin on Sat Dec 16 05:50:33 GMT 2023 , Edited by admin on Sat Dec 16 05:50:33 GMT 2023
|
PRIMARY | |||
|
DBSALT002733
Created by
admin on Sat Dec 16 05:50:33 GMT 2023 , Edited by admin on Sat Dec 16 05:50:33 GMT 2023
|
PRIMARY | |||
|
E6JGE99TEM
Created by
admin on Sat Dec 16 05:50:33 GMT 2023 , Edited by admin on Sat Dec 16 05:50:33 GMT 2023
|
PRIMARY | |||
|
CHEMBL1235872
Created by
admin on Sat Dec 16 05:50:33 GMT 2023 , Edited by admin on Sat Dec 16 05:50:33 GMT 2023
|
PRIMARY | |||
|
23725031
Created by
admin on Sat Dec 16 05:50:33 GMT 2023 , Edited by admin on Sat Dec 16 05:50:33 GMT 2023
|
PRIMARY | |||
|
76578-81-9
Created by
admin on Sat Dec 16 05:50:33 GMT 2023 , Edited by admin on Sat Dec 16 05:50:33 GMT 2023
|
PRIMARY | |||
|
AA-100
Created by
admin on Sat Dec 16 05:50:33 GMT 2023 , Edited by admin on Sat Dec 16 05:50:33 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD